» Articles » PMID: 35003088

An Integrated Platform for Serological Detection and Vaccination of COVID-19

Overview
Journal Front Immunol
Date 2022 Jan 10
PMID 35003088
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an ongoing pandemic. Detection and vaccination are essential for disease control, but they are distinct and complex operations that require significant improvements. Here, we developed an integrated detection and vaccination system to greatly simplify these efforts. We constructed recombinant baculoviruses to separately display the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2. Insect cells infected by the recombinant baculoviruses were used to generate a cell-based system to accurately detect patient serum. Notably, although well-recognized by our newly developed detection system in which S-displaying insect cells acted as antigen, anti-S antibodies from many patients were barely detectable by Western blot, evidencing that COVID-19 patients primarily produce conformation-dependent anti-S antibodies. Furthermore, the same baculovirus constructs can display N (N-Bac) or S (S-Bac) on the baculovirus envelope and serve as vector vaccines. Animal experiments show that S-Bac or N-Bac immunization in mice elicited a strong and specific antibody response, and S-Bac in particular stimulated effective neutralizing antibodies without the need for adjuvant. Our integrated system maintains antigen conformation and membrane structure to facilitate serum detection and antibody stimulation. Thus, compared with currently available technologies, our system represents a simplified and efficient platform for better SARS-CoV-2 detection and vaccination.

Citing Articles

Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study.

Wu Y, Wang X, Huang Y, Chen R, Xu Y, Wei W Viruses. 2024; 16(9).

PMID: 39339957 PMC: 11437430. DOI: 10.3390/v16091481.


Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic infection.

Masip Y, Caeiro L, Cosenza M, Postan M, Molina G, Taboga O Front Cell Infect Microbiol. 2024; 14:1297321.

PMID: 38481660 PMC: 10933115. DOI: 10.3389/fcimb.2024.1297321.


The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions.

Dofuor A, Quartey N, Osabutey A, Boateng B, Lutuf H, Osei J Clin Pathol. 2023; 16:2632010X231218075.

PMID: 38144436 PMC: 10748929. DOI: 10.1177/2632010X231218075.


SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19.

Wang Y, Tsai C, Wang Y, Yen L, Chang Y, Sun J Infection. 2023; 52(3):955-983.

PMID: 38133713 PMC: 11143065. DOI: 10.1007/s15010-023-02142-4.


RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.

Batmunkh B, Otgonbayar D, Shaarii S, Khaidav N, Shagdarsuren O, Boldbaatar G PLoS One. 2023; 18(12):e0295167.

PMID: 38064430 PMC: 10707641. DOI: 10.1371/journal.pone.0295167.


References
1.
Woo P, Lau S, Wong B, Tsoi H, Fung A, Kao R . Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol. 2005; 43(7):3054-8. PMC: 1169156. DOI: 10.1128/JCM.43.7.3054-3058.2005. View

2.
Kost T, Condreay J, Jarvis D . Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005; 23(5):567-75. PMC: 3610534. DOI: 10.1038/nbt1095. View

3.
Huang Y, Yang C, Xu X, Xu W, Liu S . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-1149. PMC: 7396720. DOI: 10.1038/s41401-020-0485-4. View

4.
Prabakaran M, Kumar S, Ashok Raj K, Wu X, He F, Zhou J . Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes. Antiviral Res. 2014; 109:149-59. DOI: 10.1016/j.antiviral.2014.06.017. View

5.
Petricciani J, Sheets R, Griffiths E, Knezevic I . Adventitious agents in viral vaccines: lessons learned from 4 case studies. Biologicals. 2014; 42(5):223-36. DOI: 10.1016/j.biologicals.2014.07.003. View